Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. Its product candidates also comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor IIb, which is in Phase I clinical trials to treat patients with gastric or gastroesophageal junction and bladder cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 as a monotherapy in various cancers. The company's FP-1039 is in Phase Ib clinical trials to treat patients with malignant pleural mesothelioma. Its preclinical product candidates include FPA150, a CD8 T cell checkpoint inhibitor antibody; FPA154, a tetravalent agonistic antibody that activates glucocorticoid-induced tumor necrosis factor receptor; and FPT155, a CD80-Fc fusion protein, which modulates signaling pathways. The company has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; collaboration agreement with Roche; and license agreements with bluebird bio, Inc., Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. Five Prime Therapeutics, Inc. was founded in 2001 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-365-5600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$49.87 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions
What is Five Prime Therapeutics' stock symbol?
Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."
How were Five Prime Therapeutics' earnings last quarter?
Five Prime Therapeutics Inc (NASDAQ:FPRX) released its quarterly earnings results on Tuesday, February, 26th. The biotechnology company reported ($1.12) EPS for the quarter, topping the Zacks' consensus estimate of ($1.32) by $0.20. Five Prime Therapeutics had a negative net margin of 281.64% and a negative return on equity of 44.55%. View Five Prime Therapeutics' Earnings History.
When is Five Prime Therapeutics' next earnings date?
What price target have analysts set for FPRX?
8 analysts have issued 12 month price targets for Five Prime Therapeutics' stock. Their forecasts range from $16.00 to $44.00. On average, they anticipate Five Prime Therapeutics' share price to reach $26.3333 in the next year. This suggests a possible upside of 100.4% from the stock's current price. View Analyst Price Targets for Five Prime Therapeutics.
What is the consensus analysts' recommendation for Five Prime Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Five Prime Therapeutics.
Has Five Prime Therapeutics been receiving favorable news coverage?
Headlines about FPRX stock have been trending somewhat positive recently, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Five Prime Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Five Prime Therapeutics' key competitors?
Some companies that are related to Five Prime Therapeutics include Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Xencor (XNCR), Allakos (ALLK), Pacira Pharmaceuticals (PCRX), Myovant Sciences (MYOV), Wave Life Sciences (WVE), Puma Biotechnology (PBYI), Opko Health (OPK), Gossamer Bio (GOSS), Prestige Consumer Healthcare (PBH), Innoviva (INVA), Corcept Therapeutics (CORT), Clovis Oncology (CLVS) and Aimmune Therapeutics (AIMT).
What other stocks do shareholders of Five Prime Therapeutics own?
Who are Five Prime Therapeutics' key executives?
Five Prime Therapeutics' management team includes the folowing people:
- Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 50)
- Mr. Francis W. Sarena, Chief Strategy Officer & Sec. (Age 48)
- Dr. Helen Louise Collins, Sr. VP & Chief Medical Officer (Age 56)
- Dr. Peder K. Jensen, Advisor & Director (Age 64)
- Mr. David V. Smith, Exec. VP, CFO & Principal Accounting Officer
Who are Five Prime Therapeutics' major shareholders?
Five Prime Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (10.45%), BlackRock Inc. (8.57%), Great Point Partners LLC (6.76%), Dimensional Fund Advisors LP (4.18%), Dimensional Fund Advisors LP (4.18%) and Northern Trust Corp (1.20%). View Institutional Ownership Trends for Five Prime Therapeutics.
Which major investors are selling Five Prime Therapeutics stock?
FPRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Squarepoint Ops LLC, Barclays PLC, MetLife Investment Advisors LLC, Fox Run Management L.L.C. and Hilltop Holdings Inc.. View Insider Buying and Selling for Five Prime Therapeutics.
Which major investors are buying Five Prime Therapeutics stock?
FPRX stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Sofinnova Investments Inc., Hudson Bay Capital Management LP, Norges Bank, BlackRock Inc., Citigroup Inc., Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. View Insider Buying and Selling for Five Prime Therapeutics.
How do I buy shares of Five Prime Therapeutics?
Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Five Prime Therapeutics' stock price today?
One share of FPRX stock can currently be purchased for approximately $13.14.
How big of a company is Five Prime Therapeutics?
Five Prime Therapeutics has a market capitalization of $466.34 million and generates $49.87 million in revenue each year. The biotechnology company earns $-140,450,000.00 in net income (profit) each year or ($4.13) on an earnings per share basis.
What is Five Prime Therapeutics' official website?
How can I contact Five Prime Therapeutics?
Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected]
MarketBeat Community Rating for Five Prime Therapeutics (NASDAQ FPRX)
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe FPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
